According to GlobalData’s medical device pipeline database, 13 Human Papilloma Virus (HPV) & Epstein-Barr Virus (EBV) Tests devices are in various stages of development globally. GlobalData’s report Human Papilloma Virus (HPV) & Epstein-Barr Virus (EBV) Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
All 13 devices of this category are in active stage of development. There are 12 products in the early stages of development, and the remaining one is in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. Human papillomavirus (HPV) and Epstein-Barr virus (EBV) are two common viruses that can cause a variety of health problems. Human papillomavirus (HPV) Tests are primarily used to screen for cervical cancer and/or identify women who may be at increased risk of cervical cancer. EBV Laboratory testing can help distinguish whether someone is susceptible to EBV infection or has a recent or past infection. The most common reason to test for EBV is to aid in the diagnosis glandular fever (also known as Infectious Mononucleosis). Additionally, patients may also be tested for EBV if they are undergoing treatment that suppresses or weakens the immune system, such as immunosuppressive medication or a transplant.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Human Papilloma Virus (HPV) & Epstein-Barr Virus (EBV) Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Human Papilloma Virus (HPV) & Epstein-Barr Virus (EBV) Tests devices. Overall, most of these Human Papilloma Virus (HPV) & Epstein-Barr Virus (EBV) Tests pipeline devices are being developed by private entities.
Key players involved in the active development of Human Papilloma Virus (HPV) & Epstein-Barr Virus (EBV) Tests include Siemens Healthcare Diagnostics, Roche Diagnostics, Hologic, Joseph Fourier University and NeuMoDx Molecular.
For a complete picture of the developmental pipeline for Human Papilloma Virus (HPV) & Epstein-Barr Virus (EBV) Tests devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
